Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 4/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 2/20 | 0.31 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | RARG | P13631 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520649 | 0.87 | CYP26A1 (0.41) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 | |
| SCHEMBL5735116 | 0.86 | CYP26A1 (0.44) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 | |
| SCHEMBL4846628 | 0.85 | CYP26A1 (0.43) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 | |
| SCHEMBL14223848 | 0.85 | CYP26A1 (0.43) | CYP26A1CYP26B1CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL4843802 | 0.84 | CYP26A1 (0.43) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 | |
| SCHEMBL5734508 | 0.83 | CYP26A1 (0.49) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 | |
| SCHEMBL4847735 | 0.83 | CYP26A1 (0.40) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 | |
| SCHEMBL4507724 | 0.83 | CYP26A1 (0.38) | CYP26A1CYP26B1TNFACACB | |
| SCHEMBL4514919 | 0.82 | CYP26A1 (0.36) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 | |
| SCHEMBL4502562 | 0.82 | CYP26A1 (0.40) | CYP26A1CYP26B1TNFCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1485368-A1 | SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | Allergan, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | ALLERGAN, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003080594-A1 | SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | ALLERGAN, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077721-A1 | Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A | RARA, CYP2R1, RXRA | CYP26A1 5/4885CYP26B1 8/4885TNF 4316/4885 |
| US-20030207937-A1 | 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | RXRA, RARA, CYP26A1 | CYP26A1 3/4885CYP26B1 7/4885TNF 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.